Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

Clinical Trial

J J López-Ibor Jr et al. Eur Neuropsychopharmacol. 1996 May.

Abstract

There is evidence of the clinical efficacy and safety of clomipramine and the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of obsessive-compulsive disorder (OCD). In the present study, we have compared the efficacy and safety of 40 mg/day of fluoxetine and 150 mg/day of clomipramine in patients with OCD, diagnosed according to DSM-IIIR. A total of 55 patients entered this 8-week, double-blind controlled study. Efficacy for both drugs was comparable. The primary efficacy criterion, the Y-BOCS Total score, did not show any significant differences between treatment arms. Response rate was higher with clomipramine, using a 25% decrease in Y-BOCS Total score as response threshold, but there were no significant differences between treatment arms using a 35% threshold. Overall safety and tolerability were good for both drugs, being slightly better for fluoxetine.

PubMed Disclaimer

Cited by

Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.
Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G. Skapinakis P, et al. Lancet Psychiatry. 2016 Aug;3(8):730-739. doi: 10.1016/S2215-0366(16)30069-4. Epub 2016 Jun 16. Lancet Psychiatry. 2016. PMID: 27318812 Free PMC article. Review.
Current trends in drug treatment of obsessive-compulsive disorder.
Decloedt EH, Stein DJ. Decloedt EH, et al. Neuropsychiatr Dis Treat. 2010 May 25;6:233-42. doi: 10.2147/ndt.s3149. Neuropsychiatr Dis Treat. 2010. PMID: 20520787 Free PMC article.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University; Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR. Katzman MA, et al. BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. BMC Psychiatry. 2014. PMID: 25081580 Free PMC article. Review.
Obsessive-compulsive disorder.
Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, van den Heuvel OA, Simpson HB. Stein DJ, et al. Nat Rev Dis Primers. 2019 Aug 1;5(1):52. doi: 10.1038/s41572-019-0102-3. Nat Rev Dis Primers. 2019. PMID: 31371720 Free PMC article. Review.

Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder - PubMed (original) (raw)